You're In! See you on September 1st
Thank you for registering for From SSRIs to Psychedelics: Where Your Role Begins and Ends. On September 1st, Paul F. Austin and Dr. Dave Rabin map what every credential level can do when a client wants off antidepressants, and how to build a prescriber relationship strong enough to carry the work.
Tuesday, September 1st at 10 AM / 1 PM ET
Important next steps:
1. Mark Your Calendar
Pro tip: Set a reminder for 10 minutes before to ensure you’re ready to join.
2. Watch Your Inbox
We’ve sent your webinar access details to your registered email address.
If you don’t see it within the next 15 minutes, please check your spam folder.
Take a moment to reflect on:
- The last time a client’s medication came up in a session, and what you did with it
- Where you draw your line today with clients on medication, and what you base it on
- A client you referred out, and what you wish you could have offered them
- The one scope or consent question you want answered live
These reflections will help you get the most from our upcoming webinar and prepare you to ask sharper questions when the live Q&A opens.
Your Free Guide, As Promised
Here’s the Clinical Primer, ready now. Read it before the session and you’ll arrive with the foundations already in place:
From SSRIs to Psychedelic Medicine: A Clinical Primer for Practitioners. The interaction between antidepressants and serotonergic psychedelics, the taper, and the criteria for a safe transition.
From SSRIs to Psychedelic Medicine: A Clinical Primer for Practitioners. The interaction between antidepressants and serotonergic psychedelics, the taper, and the criteria for a safe transition.
Want to Dive Deeper?
Deepen your understanding of SSRIs & psychedelics with these curated resources that complement what you’ll learn at the training:
New here? Watch the session this one grew out of
This webinar picks up where our last one left off. If you’d like the full picture before September 1st, the replay of From SSRIs to Psychedelics: What Happens In Between covers the interaction risk, the ketamine bridge, and the readiness criteria – the foundation this session builds on.
Ketamine, SSRIs & the Future of Psychedelic Therapy
Paul F. Austin sits down with Dr. Remi Drozd, founder of Lucid Therapeutics, to explore ketamine, SSRIs, and the changing landscape of psychedelic mental health care. They discuss tapering psychiatric medications, preparing patients for psilocybin, and what future FDA approvals mean for insurance, access, and clinic infrastructure.
Microdosing on SSRIs? A Psychiatrist’s Take
Paul F. Austin and Dr. Dave Rabin on microdosing, SSRIs, and why the taper comes first. Dr. Rabin lays out the interaction risk and the ketamine bridge in his own words.
SSRIs vs. Psychedelics: From Blunting to Rebooting
Paul F. Austin and Dr. Robin Carhart-Harris on what the head-to-head trial against escitalopram actually showed, and why a researcher with nothing to sell is skeptical of the “stay on your SSRI” position.
We look forward to seeing you at the webinar!
